|Articles|May 30, 2019
VISUMAX 800 - Why speed matters
Author(s)Detlev R.H. Breyer, MD
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
4
A vascular link: erectile dysfunction may signal glaucoma risk in men
5













